Search

Displaying results 1431 - 1440 of 10000 in total
  1. Drug

    Carvedilol

    go.drugbank.com/drugs/DB01136
    ApprovedInvestigational

    [A182306] Carvedilol was granted FDA approval on 14 September 1995.[L7889] … [L7889,L7892] The dual action of carvedilol is advantageous in combination therapies as moderate doses of 2 drugs have a decreased incidence of adverse effects compared to high dose monotherapy in the

    Mixtures: Co-Dilatrend 25 mg/12,5 mg - FilmtablettenCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    OTL-201

    go.drugbank.com/drugs/DB17652
    Experimental

    OTL-201 is an investigational hematopoietic stem cell (HSC) gene therapy being developed by Orchard Therapeutics for the treatment of mucopolysaccharidosis type IIIA (MPS-IIIA). … It consists of a lentiviral vector to insert a functional copy of the human N-Sulfoglucosamine Sulfohydrolase (SGSH) gene into autologous CD34+ hematopoietic stem cells.[L45973]

  3. Drug

    Etamsylate

    go.drugbank.com/drugs/DB13483
    Investigational

    Products: DICYNONE INJECTION 250 mg/2 ml, DICYNONE® AMPOLLAS 250 MG
  4. Drug

    BN-201

    go.drugbank.com/drugs/DB18295
    Investigational

    Synonyms: N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-, Glycinamide, n-(2-(2-fluorophenyl)ethyl)glycyl-n-(2-methylpropyl)glycyl-n2-(3-(2-oxo-1-pyrrolidinyl)propyl)-
  5. Drug

    Polidocanol

    go.drugbank.com/drugs/DB06811
    ApprovedInvestigational

    Polidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower … The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.

    Mixtures: DENTINOX 3.4 MG/G + 3.2 MG/G + 150 MG/G JEL, 20 G, DENTINOX 3.4 MG/G + 3.2 MG/G + 150 MG/G JEL, 10 GCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Petrolatum

    go.drugbank.com/drugs/DB11058
    ApprovedInvestigational

    It is used as an ointment base, topical protectant, and lubricant.

    Mixtures: Dg Baby Vitamins A and D, Dg Health HemorrhoidalCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. … A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane

    Mixtures: Animi-3 with Vitamin D, FOLEX 308MG/350 MCG KAPLI TABLET, 100 ADETProducts: FOLSET 5 MG TABLET, FOLAS 5 MG TABLET, 50 ADET
  8. Drug

    BCG vaccine

    go.drugbank.com/drugs/DB12768
    ApprovedInvestigationalWithdrawn

    BCG vaccine has been investigated for the treatment of Neoplasms, Bladder Cancer, Neoplasms by Site, Urologic Diseases, and Urologic Neoplasms, among others.

    Products: BCG CULTURE SSI 30 MG 4 VIAL, SII-ONCO-BCG (Powder for Intravesical Instillation) BCG Live USP. 1 vial of 40 mg/ml
  9. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    [A264329] Ixazomib was approved by the FDA on November 20, 2015, making it the first oral proteasome inhibitor approved in the US. … [A264319] It was later approved by Health Canada on August 3, 2016,[L51239] and by the EMA on November 21, 2016.

    Products: NİNLARO 2.3 MG MG KAPSÜL, 3 ADET, NINLARO® 3.0 MG
  10. Drug

    Nusinersen

    go.drugbank.com/drugs/DB13161
    ApprovedInvestigational

    An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S. … FDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection.

    Products: SPİNRAZA 12 MG/5 ML INTRATEKAL ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, SPINRAZA ®12 MG SOLUCION INYECTABLE